生物治疗启动46周后磁共振小肠造影表现可预测克罗恩病长期不良结局
本研究纳入89例克罗恩病患者,在启动生物治疗46周时行磁共振小肠造影(MRE)并前瞻性随访2年。随访期间46例(51.7%)出现至少1种不良结局。多因素分析显示,任何肠段持续存在严重病变(MaRIA≥11)与手术风险升高相关(OR 11.6),穿透性病变、爬行脂肪及并发症亦与特定不良结局相关。作者认为第46周MRE表现可预测长期不良结局。
要点
- 46周MRE任何肠段持续严重病变(MaRIA≥11)与手术风险升高相关(OR 11.6)。
- 穿透性病变与手术风险升高相关(OR 3.4)。
- 爬行脂肪与住院风险(OR 5.1)和需用糖皮质激素风险(OR 16.0)升高相关。
核心结论
- 生物治疗启动第46周时的MRE表现可预测克罗恩病患者的长期不良结局。
- 作者认为,对于持续存在严重炎症病变、克罗恩病相关并发症或爬行脂肪的患者,可能需要治疗干预。
研究设计与样本
- 前瞻性随访研究:克罗恩病患者在启动生物治疗46周时行MRE,随后前瞻性随访2年。
- 共纳入89例患者,采用逻辑回归分析评估不同影像学表现对预设不良结局的预测价值。
主要发现
- 随访期间46例(51.7%)出现至少1种不良结局:40例(44.9%)临床复发,18例(20.2%)需手术,8例(9%)需内镜下球囊扩张,12例(13.5%)住院,7例(7.8%)需糖皮质激素。
- 多因素分析中,任何肠段持续存在严重病变(MaRIA≥11)与手术风险升高相关[OR 11.6(1.5-92.4)],与手术和/或内镜下球囊扩张风险升高相关[OR 6.3(1.3-30.2)],与临床复发风险升高相关[OR 4.6(1.6-13.9)]。
- 穿透性病变与手术风险升高相关[OR 3.4(1.2-9.9)]。
- 爬行脂肪与住院风险升高相关[OR 5.1(1.1-25.0)],与需用糖皮质激素风险升高相关[OR 16.0(1.2-210.0)]。
- 存在并发症(狭窄性和/或穿透性病变)与出现至少1种不良结局相关[OR 3.35(1.3-8.5)]。
关键数值与推荐
- 持续严重病变定义为任何肠段MaRIA≥11。
- 并发症定义为狭窄性和/或穿透性病变。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Magnetic resonance enterography (MRE) depicts transmural changes in response to biological treatment for Crohn's disease (CD); however, the long-term prognostic significance of these findings is unknown. The primary objective of this study was to identify findings on MRE 46 weeks after initiating biological treatment that predict adverse long-term outcomes. METHODS: Patients with CD underwent MRE 46 weeks after initiating biological treatment and were prospectively followed for 2 years. A logistic regression analysis was performed to assess the prognostic value of different radiologic findings for various predefined adverse outcomes. RESULTS: Of the 89 patients included, 46 (51.7%) had ≥1 adverse outcome during follow-up: 40 (44.9%) had clinical recurrence; 18 (20.2%) required surgery, 8 (9%) endoscopic balloon dilation, 12 (13.5%) hospitalization and 7 (7.8%) required corticosteroids. In the multivariate analysis, persistence of severe lesions (MaRIA ≥11) in any intestinal segment was associated with an increased risk of surgery [OR 11.6 (1.5-92.4)], of surgery and/or endoscopic balloon dilation [OR 6.3 (1.3-30.2)], and of clinical relapse [OR 4.6 (1.6-13.9)]. Penetrating lesions were associated with surgery [OR 3.4 (1.2-9.9)]. Creeping fat with hospitalization [OR 5.1 (1.1-25.0)] and corticosteroids requirement [OR 16.0 (1.2-210.0)]. The presence of complications (stricturing and/or penetrating lesions) was associated with having ≥1 adverse outcome [OR 3.35 (1.3-8.5)]. CONCLUSION: MRE findings at week-46 after initiating biological therapy can predict long-term adverse outcomes in CD. Therapeutic intervention may be required in patients with persistence of severe inflammatory lesions, CD-associated complications, or creeping fat.
引用
- Fernández-Clotet A, Ordás I, Masamunt MC, et al. Magnetic resonance enterography findings 46 weeks after initiation of biological therapy predict long-term adverse outcomes in Crohn's disease. Aliment Pharmacol Ther. 2024. PMID: 38650481. doi:10.1111/apt.17968
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。